August 2, 2012 — Using a microneedle to inject drugs into the suprachoroidal space may provide a method for drug delivery to the posterior segment of the eye that is less invasive and more targeted ...

ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

ALPHARETTA, Ga., March 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to ...

Clearside’s patented, proprietary suprachoroidal space (SCS ®) injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The Company ...

A panel of ophthalmologists defined points of consensus for suprachoroidal space injections based on current published evidence. IVT is the primary method of delivering therapeutics in the eye, ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this Healio Video Perspective from the AAO meeting, Dilraj Grewal, MD, FASRS, of Duke Eye Center ...

- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration of ...

TEL AVIV, Israel, May 3, 2026 /PRNewswire/ -- Everads Therapy, a clinical-stage company leveraging its novel suprachoroidal delivery technology to advance the treatment of retinal diseases, today ...

Patients with macular edema (ME) associated with uveitis (UME) are at risk for vision loss and decreased quality of life, and they often experience high health care costs and rates of workforce ...

Summary: This presentation compared the benefits of TKIs in wet AMD management, focusing on pan-VEGF receptors blockage and extended drug delivery while acknowledging the limitations of current ...